Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
1 file | 681.30 KB
Add to list
  1. Search results
  2. Epithelial-mesenchymal transition (EM...

Epithelial-mesenchymal transition (EMT) as a therapeutic target

Sven Jonckheere, Jamie Adams, Dominic De Groote (UGent) , Kyra Campbell, Geert Berx (UGent) and Steven Goossens (UGent)
(2022) CELLS TISSUES ORGANS. 211(2). p.157-182
Author
Organization
Abstract
Metastasis is the spread of cancer cells from the primary tumour to distant sites and organs throughout the body. It is the primary cause of cancer morbidity and mortality, and is estimated to account for 90% of cancer-related deaths. During the initial steps of the metastatic cascade, epithelial cancer cells undergo an epithelial-mesenchymal transition (EMT), and as a result become migratory and invasive mesenchymal-like cells while acquiring cancer stem cell properties and therapy resistance. As EMT is involved in such a broad range of processes associated with malignant transformation, it has become an increasingly interesting target for the development of novel therapeutic strategies. Anti-EMT therapeutic strategies could potentially not only prevent the invasion and dissemination of cancer cells, and as such prevent the formation of metastatic lesions, but also attenuate cancer stemness and increase the effectiveness of more classical chemotherapeutics. In this review, we give an overview about the pros and cons of therapies targeting EMT and discuss some already existing candidate drug targets and high-throughput screening tools to identify novel anti-EMT compounds.(c) 2021 S. Karger AG, Basel
Keywords
NOTCH SIGNALING PATHWAY, NF-KAPPA-B, CANCER INVASION, DRUG-RESISTANCE, CELL PLASTICITY, E-CADHERIN, DROSOPHILA-MELANOGASTER, MOLECULAR-MECHANISMS, DNA METHYLATION, SCREENING ASSAY, EMT, Therapy, Metastasis, Drug screening, Drosophila melanogaster, Zebrafish

Downloads

  • Download
    (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 681.30 KB

Citation

Please use this url to cite or link to this publication:

MLA
Jonckheere, Sven, et al. “Epithelial-Mesenchymal Transition (EMT) as a Therapeutic Target.” CELLS TISSUES ORGANS, vol. 211, no. 2, 2022, pp. 157–82, doi:10.1159/000512218.
APA
Jonckheere, S., Adams, J., De Groote, D., Campbell, K., Berx, G., & Goossens, S. (2022). Epithelial-mesenchymal transition (EMT) as a therapeutic target. CELLS TISSUES ORGANS, 211(2), 157–182. https://doi.org/10.1159/000512218
Chicago author-date
Jonckheere, Sven, Jamie Adams, Dominic De Groote, Kyra Campbell, Geert Berx, and Steven Goossens. 2022. “Epithelial-Mesenchymal Transition (EMT) as a Therapeutic Target.” CELLS TISSUES ORGANS 211 (2): 157–82. https://doi.org/10.1159/000512218.
Chicago author-date (all authors)
Jonckheere, Sven, Jamie Adams, Dominic De Groote, Kyra Campbell, Geert Berx, and Steven Goossens. 2022. “Epithelial-Mesenchymal Transition (EMT) as a Therapeutic Target.” CELLS TISSUES ORGANS 211 (2): 157–182. doi:10.1159/000512218.
Vancouver
1.
Jonckheere S, Adams J, De Groote D, Campbell K, Berx G, Goossens S. Epithelial-mesenchymal transition (EMT) as a therapeutic target. CELLS TISSUES ORGANS. 2022;211(2):157–82.
IEEE
[1]
S. Jonckheere, J. Adams, D. De Groote, K. Campbell, G. Berx, and S. Goossens, “Epithelial-mesenchymal transition (EMT) as a therapeutic target,” CELLS TISSUES ORGANS, vol. 211, no. 2, pp. 157–182, 2022.
@article{8694967,
  abstract     = {{Metastasis is the spread of cancer cells from the primary tumour to distant sites and organs throughout the body. It is the primary cause of cancer morbidity and mortality, and is estimated to account for 90% of cancer-related deaths. During the initial steps of the metastatic cascade, epithelial cancer cells undergo an epithelial-mesenchymal transition (EMT), and as a result become migratory and invasive mesenchymal-like cells while acquiring cancer stem cell properties and therapy resistance. As EMT is involved in such a broad range of processes associated with malignant transformation, it has become an increasingly interesting target for the development of novel therapeutic strategies. Anti-EMT therapeutic strategies could potentially not only prevent the invasion and dissemination of cancer cells, and as such prevent the formation of metastatic lesions, but also attenuate cancer stemness and increase the effectiveness of more classical chemotherapeutics. In this review, we give an overview about the pros and cons of therapies targeting EMT and discuss some already existing candidate drug targets and high-throughput screening tools to identify novel anti-EMT compounds.(c) 2021 S. Karger AG, Basel}},
  author       = {{Jonckheere, Sven and Adams, Jamie and De Groote, Dominic and Campbell, Kyra and Berx, Geert and Goossens, Steven}},
  issn         = {{1422-6405}},
  journal      = {{CELLS TISSUES ORGANS}},
  keywords     = {{NOTCH SIGNALING PATHWAY,NF-KAPPA-B,CANCER INVASION,DRUG-RESISTANCE,CELL PLASTICITY,E-CADHERIN,DROSOPHILA-MELANOGASTER,MOLECULAR-MECHANISMS,DNA METHYLATION,SCREENING ASSAY,EMT,Therapy,Metastasis,Drug screening,Drosophila melanogaster,Zebrafish}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{157--182}},
  title        = {{Epithelial-mesenchymal transition (EMT) as a therapeutic target}},
  url          = {{http://doi.org/10.1159/000512218}},
  volume       = {{211}},
  year         = {{2022}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: